Controversies in Determination of Epoetin (Recombinant Human Erythropoietin) Dosages
- 1 June 1992
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 22 (6) , 409-415
- https://doi.org/10.2165/00003088-199222060-00001
Abstract
No abstract availableThis publication has 42 references indexed in Scilit:
- Clinical Pharmacokinetics of Epoetin (Recombinant Human Erythropoietin)Clinical Pharmacokinetics, 1991
- Effect of Recombinant Human Erythropoietin Therapy on Blood Pressure in Hemodialysis PatientsAmerican Journal of Nephrology, 1991
- Pharmacokinetics and Dose Response after Intravenous and Subcutaneous Administration of Recombinant Erythropoietin in Patients on Regular Haemodialysis Treatment or Continuous Ambulatory Peritoneal DialysisNephron, 1991
- The Response to Recombinant Human Erythropoietin in Patients with the Anemia of End-Stage Renal Disease Is Correlated with Serum Carnitine LevelsNephron, 1991
- Recombinant Human Erythropoietin for Patients with AIDS Treated with ZidovudineNew England Journal of Medicine, 1990
- Treatment of the Anemia of Progressive Renal Failure with Recombinant Human ErythropoietinNew England Journal of Medicine, 1989
- INTRAPERITONEAL ERYTHROPOIETINThe Lancet, 1988
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986
- A Comparison of Androgens for Anemia in Patients on HemodialysisNew England Journal of Medicine, 1981